Dianthus Therapeutics (DNTH) EBIT Margin (2022 - 2025)
Historic EBIT Margin for Dianthus Therapeutics (DNTH) over the last 4 years, with Q3 2025 value amounting to 10173.74%.
- Dianthus Therapeutics' EBIT Margin fell 87971300.0% to 10173.74% in Q3 2025 from the same period last year, while for Sep 2025 it was 4558.41%, marking a year-over-year decrease of 30044500.0%. This contributed to the annual value of 1633.74% for FY2024, which is 709300.0% up from last year.
- As of Q3 2025, Dianthus Therapeutics' EBIT Margin stood at 10173.74%, which was down 87971300.0% from 18096.89% recorded in Q2 2025.
- Dianthus Therapeutics' 5-year EBIT Margin high stood at 703.67% for Q3 2022, and its period low was 18096.89% during Q2 2025.
- Moreover, its 4-year median value for EBIT Margin was 1705.52% (2023), whereas its average is 3631.93%.
- In the last 5 years, Dianthus Therapeutics' EBIT Margin skyrocketed by 6343800bps in 2024 and then plummeted by -169050500bps in 2025.
- Over the past 4 years, Dianthus Therapeutics' EBIT Margin (Quarter) stood at 910.04% in 2022, then plummeted by -234bps to 3041.31% in 2023, then increased by 21bps to 2406.94% in 2024, then tumbled by -323bps to 10173.74% in 2025.
- Its last three reported values are 10173.74% in Q3 2025, 18096.89% for Q2 2025, and 2852.71% during Q1 2025.